According to reports from Business Standard, Samsung Biologics Co. has agreed to acquire Switzerland's PolyPeptide Group AG in an all-cash deal valued at approximately 1.46 billion Swiss francs ($1.8 billion). The South Korean company is offering 44.31 Swiss francs per share for PolyPeptide, representing a 6.1% premium over the company's Friday close and 40% more than when market rumors regarding potential acquisition first emerged. As reported by CNBC, the transaction will be financed entirely from Samsung Biologics' existing balance sheet and credit facilities, making it the largest biopharmaceutical acquisition in South Korean history. According to Bloomberg, PolyPeptide's board unanimously recommended shareholders accept the offer, with the company's largest shareholder Draupnir Holding (55.65% stake) committed irrevocably to tender all of its shares. However, the real strategic value lies in PolyPeptide's critical position in the GLP-1 drug supply chain, manufacturing the molecular building blocks for blockbuster drugs like semaglutide and tirzepatide that have reshaped the pharmaceutical industry over the past three years.
As reported by Business Standard, shares of Samsung Biologics declined as much as 3.3% in Seoul on Monday following the announcement. In contrast, PolyPeptide shares jumped as much as 5.6% on the news. The acquisition is expected to be completed toward the end of 2026, with Samsung requiring a minimum acceptance threshold of 66 and two-thirds percent of PolyPeptide's fully diluted shares. According to CNBC, the tender offer launch is scheduled for the end of August, with the deal targeting completion by year-end subject to regulatory approvals. The transaction represents the largest in a series of biopharmaceutical acquisitions that have accelerated globally as pharmaceutical companies race to lock in manufacturing capacity for the next decade, with the GLP-1 boom creating a structural shortage of manufacturing capacity that has exposed capacity questions across the industry.
According to the report, PolyPeptide operates manufacturing sites across Sweden, Belgium, France, the US and India, with capabilities spanning research and development, process development and commercial manufacturing. The acquisition strengthens Samsung Biologics' presence in the contract development and manufacturing market by adding PolyPeptide's peptide manufacturing capabilities, as drugmakers ramp up demand for peptide-based medicines, including treatments for obesity and metabolic diseases. As reported by CNBC, PolyPeptide brings 70 years of peptide chemistry expertise and a portfolio of more than 1,000 therapeutic peptides, positioning it as one of the few contract manufacturers with both institutional knowledge and physical infrastructure to produce GLP-1 active pharmaceutical ingredients at commercial scale. According to Bloomberg, this combination is precisely what Samsung needs and cannot easily build from scratch, with the deal compressing the timeline from a decade-long organic buildout to the six months Samsung estimates for regulatory clearance. The acquisition gives Samsung a complementary capability it cannot easily build from scratch, at least not quickly enough to capture the current wave of demand, as biologics and peptides are manufactured through fundamentally different processes.
As reported by Business Standard, Morgan Stanley analyst Mi Hyun Kim described the purchase as "positive," noting that the peptides drug market is growing rapidly thanks to GLP-1 drugs. PolyPeptide specializes in the development and manufacturing of synthetic peptides related to metabolism, notably targeting obesity and diabetes, and has been going through a turnaround which was welcomed by investors while ramping up new facilities. According to CNBC, the deal represents a "transformational opportunity to accelerate strategic ambitions at scale," with PolyPeptide's Swiss technical leadership expected to remain in place under the combined structure. PolyPeptide Chairman Peter Wilden described the offer as delivering "immediate, certain value" while representing a "transformational opportunity to accelerate strategic ambitions at scale." The characterization applies to both parties, as Samsung gains a capability it cannot replicate quickly, while PolyPeptide gains access to Samsung's client relationships, capital, and manufacturing footprint in markets where it has had limited commercial reach, particularly the United States and Asia. This acquisition is part of a broader wave of CDMO consolidation globally over the past two years, as companies race to build integrated platforms that can serve the full lifecycle of modern drugs, with the GLP-1 boom and broader trend toward outsourcing drug production changing the economics of contract manufacturing from historically fragmented, margin-thin business to one where scale matters more than ever.
According to the report, Swiss law firm Homburger and Morgan Stanley advised PolyPeptide, while JPMorgan Chase & Co. acted as the financial adviser to Samsung Biologics. O'Melveny & Myers LLP and Schellenberg Wittmer Ltd provided legal counsel for the transaction, which adds to rising deal activity involving Swiss companies in the current market environment. Ernst and Young Han Young provided tax and accounting advice for the transaction. The deal is part of a broader trend of biopharmaceutical acquisitions as pharmaceutical companies race to secure manufacturing capacity for the next decade, with the GLP-1 boom creating a structural shortage of manufacturing capacity that has exposed capacity questions across the industry. In a world where GLP-1 drugs alone could represent hundreds of billions in annual sales by the end of the decade, controlling the capacity to make them is not a supporting role but a lead one, as every biotech developing a GLP-1 or GLP-1 adjacent molecule needs a manufacturing partner, and the leverage of CDMOs capable of serving that need is growing.
